FTC makes second request on proposed Pfizer buy of Seagen
The US Federal Trade Commission (FTC) has issued a second request to Seagen (Nasdaq: SGEN) and Pfizer (NYSE: PFE) regarding the $43 billion acquisition of Seagen by Pfizer, the former announced in a Securities and Exchange Commission filing after the close of trading on Friday.
Second requests require both parties to provide additional information to assess the legality of the transaction, though they can be broad in nature, investigating issues such as existing or potential competition, drug pricing, or off-label usage of certain products.
Pfizer previously conducted a 'pull and refile' strategy to potentially avoid a second request, noted SVB Securities analyst Dr Andrew Berens. Despite the second request, Seagen’s 8-K states that the expected timeline remains unchanged, with closing expected in late 2023 or early 2024. The timeline for processing of a second request can vary, though a MEDACorp key opinion leader (KOL) indicated that second requests often take six to nine months for the involved parties to comply.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze